Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Flagrante Delictu who wrote (14924)	2/12/1998 7:33:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Bernie, The street doesn't have a clue about LGND's value. The IL-4 antagonist could be worth 100s of millions (asthma is a very large market): thestreet.com LGND will keep putting out the data and the street will eventually figure things out.

To: Flagrante Delictu who wrote (14924)	2/12/1998 7:41:00 PM
From: Andrew H	Read Replies (3) \| Respond to of 32384

>>Even if so, there could be plenty of unrecognized value left. Bernie<< I take it that you are talking about unrecognized value that we on the thread already recognize. We should also take into consideration the value that seems to be created simply by virtue of the fact of LGND's extraordinary peipeline and technology platforms--like the diabetes discovery, the breast cancer discovery and the leptin discovery--although it is hard to predict exactly how any one of these will turn out, I think we can predict the ongoing nature of such unexpected discoveries. These alone may be worth the price of the stock.